This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by AbbVie Inc.
Response for the overall study population was an American College of Rheumatology 20% response (ACR20).
Response for the subgroup with moderate-to-severe psoriasis was an ACR20 plus 75% improvement in Psoriasis Area and Severity Index (PASI75).
Reference
Strand V et, al. Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors in the Treatment of Psoriatic Arthritis: Economic and Clinical Results From a Modeling Study. Internet Document : (plus poster) abstr. P2526, 4 Mar 2016. Available from: URL: https://www.aad.org/eposters/Submissions/getFile.aspx?id=2526&type=sub
Rights and permissions
About this article
Cite this article
Early TNFi use improves outcomes for psoriatic arthritis. PharmacoEcon Outcomes News 749, 16 (2016). https://doi.org/10.1007/s40274-016-2903-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-2903-x